Clinical trials: Clostridium Difficile
Clostridium Difficile Infection
A Safety Trial to Evaluate an Orally Ingested Yeast Modified to Express a Tetra-specific Anti-toxin for Clostridioides Difficile
This is a Phase 1, first-in-human, double-blind, placebo-controlled, adaptive-design, single-site study, involving dose exploration cohorts.
- Trial name
- NCT07649096
- Testing
- FZ002
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Clostridium Difficile Infections
Safety Registry of a Fecal Microbiota Transplant Cohort
Clostridium difficile infection (CDI) is a major cause of infectious diarrhea and the most important cause of nosocomial diarrhea. Recurrent forms are a major problem with this infection.
- Trial name
- COSMIC-FMT (NCT06311006)
- Where
- France
- Volunteers
- 305 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Clostridioides Difficile, Vancomycin Resistance Enterococcus Faecium
Primary Prophylaxis of Clostridioides Difficile Infection With Oral Vancomycin
The purpose of this study is to evaluate the ability of oral vancomycin in preventing Clostridioides difficile infection (CDI) in patients that are simultaneously receiving antibiotics.
- Trial name
- NCT07221708
- Testing
- Vancomycin (POC)
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Clostridioides Difficile Infection, Healthcare Associated Infection
Evaluation of GeoHAI Implementation
Geographic Information Systems (GIS) and spatial analysis have become important tools in public health informatics but have rarely been applied to the hospital setting.
- Trial name
- NCT05612672
- Testing
- GeoHAI
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Ohio State University
Clostridioides Difficile Infection
Safety and Tolerability of AZD5148 in Japanese Participants
The purpose of this study is to measure safety, tolerability and PK of a single dose of AZD5148 administered via IV bolus or IM injection in healthy Japanese participants.
- Trial name
- NCT06639997
- Testing
- AZD5148
- Where
- Japan
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Clostridium Difficile Infection (CDI)
Study of Metronidazole Delayed-Release Capsules in Comparison With Immediate-Release Tablets (Flagyl) for Safety and Pharmacokinetics
Clostridium difficile Infection (CDI) also referred to as Clostridium difficile associated diarrhea (CDAD) is an infectious disease that is commonly associated with taking broad-spectrum antimicrobials and certain cancer…
- Trial name
- NCT07251127
- Testing
- Delayed-release metronidazole, Immediate-release metronidazole
- Where
- India
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Gateway Pharmaceutical LLC
Clostridium Difficile
Effect of Expanding (Gloving) Barrier Precautions for Reducing Clostridium Difficile Acquisition (and Infection) in VA
Clostridium difficile (C. difficile) is a major pathogen causing serious healthcare-associated diarrheal illness in patients. Prevention of healthcare facility-onset C. difficile infection (CDI) is essential.
- Trial name
- GLORI (NCT04036058)
- Testing
- Universal gloving
- Where
- 6 sites in United States
- Volunteers
- 780 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Clostridium Difficile Immunisation, Diphtheria
Study on the Safety and Immunogenicity of Boostrix Vaccine in Pregnant Malian Women and Their Infants
This is a phase II, randomized, double-blind, active-controlled study to evaluate the safety, immunogenicity, and effect on infant immune responses of a single dose of Tetanus diphtheria acellular pertussis vaccine (Tdap) in…
- Conditions
- Clostridium Difficile Immunisation, Diphtheria, Diphtheria Immunisation, Pertussis
- Trial name
- NCT03589768
- Testing
- Tetanus and Diphtheria Toxoids Adsorbed, Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed onto aluminum hydroxide
- Where
- 2 sites in United States, Mali
- Volunteers
- 399 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Clostridium Difficile Infection Recurrence
Bacillus Velezensis DSM 33864 for Reduction of the Risk of Recurrent Clostridioides Difficile Infections
The purpose of this study is to determine whether a single strain capsulated probiotic, when used after standard C. difficile antibiotic therapy, is effective in reducing the risk of infection recurrence mediated by a decrease in…
- Trial name
- NCT05606159
- Testing
- Bacillus velezensis DSM 33864
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Novozymes A/S
Clostridium Difficile
Effects of Gastric Acid on Colonic Microbiome
The colonic microbiome is essential in human health and disease. Clostridium difficile-associated diarrhea (CDAD), a highly morbid form of infectious diarrhea, is caused by antibiotics which perturb the microbiome and allow C.
- Trial name
- NCT01901276
- Testing
- Omeprazole 40 mg bid
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Daniel Freedberg, MD
Clostridium Difficile Infection
A Study to Assess the Effect of Doctor's Biome Medical Food in Individuals With Clostridium Difficile Infection
A randomized, double-blind, placebo-controlled, pilot clinical study to assess the effect of Doctor's Biome Medical Food (DBMF) in individuals with Clostridium difficile infection (CDI)
- Trial name
- NCT06367504
- Testing
- DBMF
- Where
- 4 sites in India
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Vedic Lifesciences Pvt. Ltd.
Antimicrobial Drug Resistance, Antibiotic Resistant Infection
Dynamics of Colonization and Infection by Multidrug-Resistant Pathogens in Immunocompromised and Critically Ill Patients
The goal of this observational study is to investigate how bacterial populations from the intestine and mouth of patients change during the hospitalization period and evaluate if some populations of specific bacteria increase or…
- Conditions
- Antimicrobial Drug Resistance, Antibiotic Resistant Infection, Clostridium Difficile, Carbapenem-Resistant Enterobacteriaceae Infection
- Trial name
- DYNAMITE (NCT06258551)
- Where
- 2 sites in United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- The Methodist Hospital Research Institute
Clostridium Difficile Associated Disease
Clostridium Difficile Vaccine 2-Dose Versus 3-Dose Study
This study will investigate a Clostridium difficile vaccine in adults 50 years of age and older. In half the adults, all 3 doses given are the Clostridium difficile vaccine, and in half the adults, 2 of the 3 doses are the…
- Trial name
- NCT03918629
- Testing
- Clostridium difficile
- Where
- 52 sites in United States
- Volunteers
- 1,994 people, healthy volunteers welcome
- Sponsor
- Pfizer
Clostridioides Difficile Infection
Clostridioides Difficile Colonisation
This study will investigate experimental colonisation with non-toxigenic C.difficile (NTCD) in healthy volunteers. Main outcomes will be safety, tolerability, dose needed to obtain colonisation with NTCD to ultimately determine…
- Trial name
- CloDiCo (NCT05693077)
- Testing
- 10E4 NTCD spores, 10E7 NTCD spores, Vancomycin Oral Capsule
- Where
- Netherlands
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Leiden University Medical Center
Clostridium Difficile Infection, Clostridium Difficile Infection Recurrence
Oral Vancomycin for Secondary Prophylaxis of Clostridium Difficile Infection (CDI)
The purpose of this study is to gain further knowledge regarding the effectiveness of vancomycin prophylaxis in preventing Clostridium difficile infections in order to guide physicians' practices.
- Trial name
- NCT04000555
- Testing
- Oral Vancomycin
- Where
- 2 sites in United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- University of South Florida
Clostridium Difficile Infection
Clostridium Difficile Vaccine Efficacy Trial
The Clover trial is evaluating an investigational vaccine that may help to prevent Clostridium difficile infection. Participants in the study are adults 50 years of age and older, who are at risk of developing Clostridium…
- Trial name
- Clover (NCT03090191)
- Testing
- Clostridium difficile vaccine
- Where
- 426 sites in United States, Argentina and 21 more
- Volunteers
- 17,535 people, healthy volunteers welcome
- Sponsor
- Pfizer
Clostridium Difficile Associated Disease
Evaluation Of Clostridium Difficile Vaccine Lot Consistency In Healthy Adults 65 To 85 Years Of Age
This study will investigate a Clostridium difficile vaccine in healthy adults 65 to 85 years of age, who will each receive 3 doses of vaccine.
- Trial name
- NCT03579459
- Testing
- Clostridium difficile vaccine
- Where
- 24 sites in United States
- Volunteers
- 1,317 people, healthy volunteers welcome
- Sponsor
- Pfizer
Clostridium Difficile Infection, Multi Drug Resistant Organisms
Establishment of the Human Intestinal and Salivary Microbiota Biobank - Gastrointestinal Diseases
This is a prospective, clinical, multicentre study aimed to collect biological samples and study microbiota from subjects with Clostridium Difficile (CDI), subjects affected by Multi Drug Resistant Organisms (MDRO) infection…
- Conditions
- Clostridium Difficile Infection, Multi Drug Resistant Organisms, Chronic Inflammatory Bowel Disease, Irritable Bowel Syndrome
- Trial name
- BIOMIS-Gastr (NCT04698148)
- Testing
- Biological sample collection, Questionnaire, Medical examination
- Where
- 3 sites in Italy
- Volunteers
- 225 people, healthy volunteers welcome
- Sponsor
- Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari
Clostridium Difficile Infection
Study of a Candidate Clostridium Difficile Toxoid Vaccine in Subjects at Risk for C. Difficile Infection
The aim of this study was to evaluate the efficacy of the Clostridium difficile vaccine to prevent primary symptomatic C. difficile infection (CDI) in participants at risk for CDI where there is a substantial unmet medical need.
- Trial name
- NCT01887912
- Testing
- C. difficile Toxoid Vaccine
- Where
- 335 sites in United States, Australia and 24 more
- Volunteers
- 9,302 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Urinary Tract Infections, Infectious Diarrhea
Creation of an E-toileting Log Through Classification of the Physical Properties of Stool and Urine Using TrueLoo™
The purpose of this study is to assess the feasibility of TrueLoo™, an Internet-connected smart toilet seat, in accurately monitoring and logging bowel movements and urinations of residents in senior living facilities across…
- Conditions
- Urinary Tract Infections, Infectious Diarrhea, Clostridium Difficile Infection, Gastrointestinal Disease
- Trial name
- NCT05008640
- Testing
- TrueLoo™
- Where
- 6 sites in United States
- Volunteers
- 143 people, healthy volunteers welcome
- Sponsor
- Toi Labs, Inc.